Harm-minimisation policies and the economics of controlling illicit drug use. The use of illicit drugs and its consequences are of major concern in Australia. Policies seeking to directly curb illicit drug use have met with mixed success and, over time, pressure has been placed on policymakers to switch toward increased reliance on harm-minimisation policies. This switch can generate adverse incentive effects by reducing the user costs of illicit drug use which acts to increase illicit drug use. ....Harm-minimisation policies and the economics of controlling illicit drug use. The use of illicit drugs and its consequences are of major concern in Australia. Policies seeking to directly curb illicit drug use have met with mixed success and, over time, pressure has been placed on policymakers to switch toward increased reliance on harm-minimisation policies. This switch can generate adverse incentive effects by reducing the user costs of illicit drug use which acts to increase illicit drug use. Cost-effectively mitigating these adverse incentive effects can improve the effectiveness of policy by promoting harm- minimisation without seriously sacrificing drug use abstinence objectives. Read moreRead less
Bargaining and the price of new pharmaceuticals in Australia: An empirical analysis. The proposed research will consider whether there is a trade-off between price and access and will identify features of the regulatory framework that contribute to delays in securing access to drugs for diseases with no alternative therapy. It will provide decision makers with the necessary information to negotiate the lowest achievable price for drugs, freeing up resources for use elsewhere in the health sector ....Bargaining and the price of new pharmaceuticals in Australia: An empirical analysis. The proposed research will consider whether there is a trade-off between price and access and will identify features of the regulatory framework that contribute to delays in securing access to drugs for diseases with no alternative therapy. It will provide decision makers with the necessary information to negotiate the lowest achievable price for drugs, freeing up resources for use elsewhere in the health sector or slowing the growth in healthcare expenditure.Read moreRead less